Physician Assistant in Sharpsburg, GA Accepting Medicare

5 Physician Assistant nurses found. Showing 1 - 5

Jennifer L Leimbach, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 131 Fischer Crossings Dr, Sharpsburg, GA 30277 Phone: 678-590-5177    Fax: 678-590-5404

John W. Schmidt, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3345 Highway 34 E, Suite 101, Sharpsburg, GA 30277 Phone: 770-502-8005    Fax: 770-502-1825

Mary S. Hall, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 3345 Highway 34 E, Suite 101, Sharpsburg, GA 30277 Phone: 770-502-8005    Fax: 770-502-1825

Anjali Latisha Trambadia, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 20 Francis Way, Suite 101, Sharpsburg, GA 30277 Phone: 770-253-0611    Fax: 770-502-0521

Kelly L Johnston, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 3345 Highway 34 E, Suite 101, Sharpsburg, GA 30277 Phone: 770-502-8005    Fax: 770-502-1825

News Archive

Research clarifies role of zinc transport mechanism in onset of obstructive pulmonary diseases

Obstructive pulmonary disease is a collective term for refractory respiratory diseases with chronic airway inflammation and excessive mucus retention that are accompanied by airway obstruction.

Public and private SARS-CoV-2 T cell receptors may be crucial for pan-coronavirus vaccines

Researchers have just established a structural basis for two spike glycoprotein epitopes of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are restricted to human leukocyte antigen (HLA) A2 molecules. More specifically, they are involved in the presentation of antigenic peptides to specific T lymphocytes and recognized by public and private T cell receptors. The research is currently available on the bioRxiv* preprint server.

Reversing protein deficiency through gene therapy can improve SMA

Reversing a protein deficiency through gene therapy can correct motor function, restore nerve signals and improve survival in mice that serve as a model for the lethal childhood disorder spinal muscular atrophy, new research shows.

BioMarin completes BMN 195 Phase 1 clinical trial for Duchenne muscular dystrophy

BioMarin Pharmaceutical Inc. announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy (DMD). The Phase 1 clinical trial was a single-center, double-blind, placebo-controlled, single-dose escalation study followed by a multiple-dose escalation study in healthy volunteers.

First Edition: January 7, 2014

Today's headlines include a range of reports about state developments related to the health law's online marketplaces as well as details regarding the latest Centers for Medicare & Medicaid Services' figures on health costs.

Read more Medical News

› Verified 3 days ago